This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PF-5212365, WAY-262531
Description: SAM-531 is an orally active serotonin 5-HT6 antagonist. Preclinical data suggests that the 5-HT6 receptor is found mainly in the central nervous system with little or no expression in peripheral tissues, which may result in greater drug selectivity with fewer side effects. Some areas the 5-HT6 receptor is found in are important for learning and memory. In preclinical models, blockade of the receptor improves cognitive function, and also reduces signs thought to reflect anxiety and depression. Blockade is accompanied by enhancement of cholinergic, glutamatergic, noradrenergic, and dopaminergic neurotransmission, together with learning-associated neuronal remodeling. The receptor may also be involved in food intake.
Deal Structure: SAM-531 was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
Additional information available to subscribers only: